Holen Sie sich die Stockscreener-App
9.21
6.88%
-0.68
Handel nachbörslich:
9.18
-0.03
-0.33%
Schlusskurs vom Vortag:
$9.89
Offen:
$10.08
24-Stunden-Volumen:
192.51K
Relative Volume:
4.62
Marktkapitalisierung:
$178.91M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+0.55%
1M Leistung:
+33.67%
6M Leistung:
+5.86%
1J Leistung:
+0.00%
1-Tages-Spanne:
$8.07
$10.28
1-Wochen-Bereich:
$8.07
$10.62
52-Wochen-Spanne:
$5.51
$11.73
Actuate Therapeutics Inc Stock (ACTU) Company Profile
Firmenname
Actuate Therapeutics Inc
Sektor
Branche
Telefon
847-986-4190
Adresse
1751 RIVER RUN, FORT WORTH
Vergleichen Sie ACTU mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACTU
Actuate Therapeutics Inc
|
9.21 | 178.91M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.03 | 129.44B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.52 | 61.42B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
615.11 | 38.44B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
269.81 | 33.29B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
241.75 | 26.95B | 3.81B | -644.79M | -669.77M | -6.24 |
Actuate Therapeutics Inc Stock (ACTU) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-22 | Eingeleitet | Craig Hallum | Buy |
| 2025-03-17 | Eingeleitet | H.C. Wainwright | Buy |
Actuate Therapeutics Inc Aktie (ACTU) Neueste Nachrichten
Lilly to pay up to $415M in ALS deal; Actuate’s mid-stage pancreatic cancer data - Endpoints News
Actuate Therapeutics Reports Positive Data From Phase 2 Study Of Elraglusib In Pancreatic Cancer - Nasdaq
Actuate Therapeutics Announces Positive Phase 2 Trial Results - TipRanks
Actuate stock jumps after cancer trial data (ACTU:NASDAQ) - Seeking Alpha
Elraglusib shows survival benefit in pancreatic cancer trial - Investing.com Australia
Actuate Therapeutics Announces Statistically Significant - GlobeNewswire
Actuate Therapeutics to Participate in Citizens Life Sciences Conference 2025 - GlobeNewswire
Craig-Hallum Sticks to Their Buy Rating for Actuate Therapeutics, Inc. (ACTU) - The Globe and Mail
Actuate Therapeutics to Present Topline Phase 2 Data of Elraglusib at 2025 ASCO Annual Meeting - Nasdaq
Actuate to Present Elraglusib Phase 2 Topline Data at the - GlobeNewswire
Actuate to Present Elraglusib Phase 2 Topline Data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - Yahoo Finance
Actuate Therapeutics (NASDAQ:ACTU) Now Covered by Analysts at Craig Hallum - Defense World
Craig-Hallum sets $21 target on Actuate Therapeutics stock By Investing.com - Investing.com Canada
What Will Actuate Therapeutics Inc (NASDAQ: ACTU) Be Like In 2025 - stocksregister.com
Pre-market Movers: CHRO, QURE, FOTA, LLY... - RTTNews
Actuate Therapeutics to Present Elraglusib Data for Advanced Salivary Gland Carcinoma at AACR Annual Meeting 2025 - Nasdaq
Actuate to Present Promising Data on Elraglusib in Advanced - GlobeNewswire
Actuate to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 2025 - Yahoo Finance
Actuate Therapeutics (NASDAQ:ACTU) Trading 6% Higher – Still a Buy? - Defense World
Bone Metastasis in Solid Tumors Market Set to Grow Substantially - openPR.com
Bone Metastasis in Solid Tumors Market Set to Grow Substantially Through 2034, DelveInsight Projects | NanaBis, Actuate Therapeutics, Mabwell Bioscience, Hoffmann-La Roche, Novartis, Upjohn, INSYS - Barchart.com
Will Actuate's Elraglusib Prove To Be A Game Changer In The Fight Against Aggressive Cancers? - RTTNews
Soft Tissue Sarcoma with Lung Metastases Treatment Market Size - openPR.com
Bone Metastasis Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Epidemiology, Statistics, Revenue, Therapies, Treatment, Companies by DelveInsight - Barchart.com
Pre-market Movers: PRTG, RNAZ, PTIX, LGMK... - RTTNews
Actuate Therapeutics Enters Stock Purchase Agreement With B. Riley Principal Capital Ii, Llc - Marketscreener.com
Actuate Therapeutics Files Prospectus To Offer, Sale Of Up To 3.9 Million Shares By B. Riley Principal Capital II, LLC - MarketScreener
Growth Driver In The Locally Advanced Pancreatic Cancer Market 2 - News Channel Nebraska Southeast
Actuate Therapeutics: Looking To Make An Impact In Pancreatic Cancer (NASDAQ:ACTU) - Seeking Alpha
Brokers Set Expectations for ACTU Q1 Earnings - Defense World
Soft Tissue Sarcoma Clinical Pipeline | 70+ Companies Driving Innovation in Treatment - openPR.com
WIN Consortium leading the future of precision cancer medicine - EurekAlert
Actuate Therapeutics (NASDAQ:ACTU) Now Covered by HC Wainwright - Defense World
HC Wainwright & Co. Initiates Coverage of Actuate Therapeutics (ACTU) with Buy Recommendation - Nasdaq
Actuate Therapeutics: Promising Phase 2 Results and Market Potential for Elraglusib in Metastatic Pancreatic Cancer - TipRanks
Actuate Therapeutics Inc. (ACTU) reports earnings - Quartz
ACTUATE THERAPEUTICS, INC. SEC 10-K Report - TradingView
Pre-market Movers: AWH, TSVT, CUTR, SNOA... - RTTNews
Neuroblastoma Pipeline 2025: Key Companies, MOA, ROA, - openPR
Ratio Chart Of U.S. Dollar Index Against 10Y U.S. Notes Is Pointing Much Lower - The Globe and Mail
Dollar Retreats on Growth Risk From US Tariffs - The Globe and Mail
Zoom Stock: Leading the Video Market After Skype’s Exit - The Globe and Mail
Pancreatic And Bile Duct Cancer Drug Market Enhancing Cybersecurity and Cloud Integration for the Future - ExpressVartha
Actuate reports progress in pancreatic cancer trial By Investing.com - Investing.com Australia
The Polycythemia Vera Market Landscape Heats Up Amid Rising Competition Among Pharma Companies | DelveInsight - The Malaysian Reserve
Candel reports extended survival in Phase II CAN-2409 trial - The Pharma Letter
Actuate Announces Completion of Enrollment in a Phase 2 - GlobeNewswire
Actuate reports progress in pancreatic cancer trial - Investing.com India
Actuate Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination with FOLFIRINOX and Losartan in Patients with Previously Untreated Metastatic Pancreatic Cancer - Yahoo Finance
BESREMi Achieves Strong Market Growth Amid Rising Demand for Polycythemia Vera Treatment - GlobeNewswire
Finanzdaten der Actuate Therapeutics Inc-Aktie (ACTU)
Es liegen keine Finanzdaten für Actuate Therapeutics Inc (ACTU) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
5.24%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):